secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001654954-24-001811
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin Q2 FY2024 net loss $7.8M; Vyleesi sale closed; pipeline catalysts ahead
-------------------------------------------------------------------------------

- Net loss of $7.8M ($0.56/share) vs net income of $2.7M ($0.25) in Q2 FY2023.
- Vyleesi net product revenue $2.0M (+98% YoY); completed asset sale to Cosette for up to $171M ($12M upfront).
- Cash $9.5M + $2.3M AR at Dec 31, 2023; added $9.2M net from Feb 2024 equity offering.
- PL9643 Phase 3 dry eye disease topline data expected Feb 2024; PL8177 UC interim analysis Q2 2024.
- Phase 2 obesity (MCR4+GLP-1) and ED (bremelanotide+PDE5i) studies to start 1H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/0001654954-24-001811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-001811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer